Oncology

Views & Analysis

ASCO 2019 Preview – in partnership with Kantar

ASCO’s 2019 conference is due to begin in just a few days’ time, highlighting the latest cutting edge cancer drugs and technology.

Views & Analysis

ASCO 2019 and the future of oncology

The future of oncology is to be showcased at ASCO 2019 when the world’s leading cancer event returns to McCormick Place in Chicago.

Views & Analysis

Adapting for success

The last two decades have seen often limited treatment options for cancers give way to therapies with increasingly complex and targeted mechanisms of action as understanding of the disease

Views & Analysis

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced

News

AZ and Daiichi to file new breast cancer drug after trial su...

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

ASCO 2019 Preview – in partnership with Kantar

ASCO 2019 and the future of oncology

Adapting for success

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi to file new breast cancer drug after trial su...

EU regulators to fast-track Janssen's multiple myeloma CAR-T

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

Oncology

Editor's Picks